The first full-cycle HPV vaccine production has been launched in Russia

Russia's first full-cycle vaccine against human papillomavirus (HPV) has been opened in the Kirov Region. This was announced on October 29 by the press service of the Industrial Development Fund (AFD).

The total investment in the development and launch of the project will amount to 7.5 billion rubles, of which 950 million were provided by the FRP in the form of a concessional loan. The new drug will be the first domestic analogue of foreign vaccines previously used in Russia.

It is clarified that HPV vaccination has been proven to reduce mortality from cervical cancer, one of the most common cancers among women under the age of 45. The production is organized according to the full cycle — from the production of the antigen to the finished dosage form, which will ensure Russia's technological sovereignty in the field of immunoprophylaxis.

It's not too late: in Russia, they can't assess the level of commitment to healthy lifestyle

Experts pointed out the lack of a clear methodology, which does not allow us to draw unambiguous conclusions about people's desire to be healthy.

Earlier, on August 18, oncogynecologist Radmir Akhmerov noted that the human papillomavirus is one of the main causes of cervical cancer. According to him, the infection is often asymptomatic, and the most dangerous strains are types 16 and 18, which are detected in most patients with this diagnosis.

All important news is on the Izvestia channel in the MAX messenger.